Novo to part ways with longtime CEO Lars Fruergaard Jørgensen, citing weight of market pressures
Under a mutual agreement with Novo Nordisk's board of directors, Lars Fruergaard Jørgensen is stepping down from the chief executive post he’s held for the past eight years. Novo didn’t mince words about the rationale behind the decision, pointing to “recent market challenges” and the precipitous decline of the company’s share price “since mid-2024.”
Under a mutual agreement with Novo Nordisk's board of directors, Lars Fruergaard Jørgensen is stepping down from the chief executive post he’s held for the past eight years. Novo didn’t mince words about the rationale behind the decision, pointing to “recent market challenges” and the precipitous decline of the company’s share price “since mid-2024.”
